Stock Events

Stock Events

Xilio Therapeutics 

$9.23
21
+$0.00+0% Friday 20:00
+$0.25+2.72%Friday 20:29After hours

Statistics

Day High
9.19
Day Low
9.19
52W High
12.74
52W Low
6.47
Volume
513
Avg. Volume
-
Mkt Cap
60.73M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.54
-1.05
-0.57
-0.08
Expected EPS
-0.82
Actual EPS
N/A

Financials

-80.05%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
43.77MRevenue
-35.04MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow XLO. It's not an investment recommendation.
Amazon
4
AMZN
NVIDIA
4
NVDA
Meta Platforms
4
META
Apple
3
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap335.14B
Merck & Co., Inc. is a global healthcare company that develops medications in oncology, competing directly with Xilio's cancer therapy focus.
Bristol-Myers Squibb
BMY
Mkt Cap130.39B
Bristol-Myers Squibb operates in the biopharmaceutical industry, focusing on cancer treatments, which aligns with Xilio's therapeutic areas.
Pfizer
PFE
Mkt Cap152.69B
Pfizer Inc. has a broad portfolio including oncology, directly competing with Xilio's cancer-focused therapies.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG specializes in biotechnology products for oncology, making it a direct competitor in the cancer treatment market.
Novartis
NVS
Mkt Cap286.78B
Novartis AG focuses on innovative medicines, including oncology, which competes with Xilio's cancer therapy developments.
AMGEN
AMGN
Mkt Cap224.63B
Amgen Inc. is a biotech company with a strong focus on oncology, competing in the same therapeutic area as Xilio.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences, Inc. is involved in the discovery, development, and commercialization of innovative therapeutics in areas including oncology.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals, Inc. is known for its innovation in biopharmaceuticals, including cancer treatments, making it a competitor.
Astrazeneca
AZN
Mkt Cap242.64B
AstraZeneca PLC is a global, science-led biopharmaceutical business that focuses on oncology, among other areas, competing with Xilio.
Johnson & Johnson
JNJ
Mkt Cap627.42B
Johnson & Johnson operates in the pharmaceuticals sector with a broad range of products, including oncology, competing with Xilio's focus.

About

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
Show more...
CEO
Rene Russo
Employees
76
Country
United States
ISIN
US98422T2096

Listings

XNAS
US
XLO
BOATS
BOATS
XLO.BOATS

0 Comments

Share your thoughts

FAQ

What is Xilio Therapeutics stock price today?▼
The current price of XLO is $9.23 USD — it has increased by +0% in the past 24 hours. Watch Xilio Therapeutics stock price performance more closely on the chart.
What is Xilio Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Xilio Therapeutics stocks are traded under the ticker XLO.
Is Xilio Therapeutics stock price growing?▼
XLO stock has risen by +0.65% compared to the previous week, the month change is a +8.84% rise, over the last year Xilio Therapeutics has showed a -6.23% decrease.
What is Xilio Therapeutics market cap?▼
Today Xilio Therapeutics has the market capitalization of 60.73M
When is the next Xilio Therapeutics earnings date?▼
Xilio Therapeutics is going to release the next earnings report on November 05, 2026.
What were Xilio Therapeutics earnings last quarter?▼
XLO earnings for the last quarter are -0.33 USD per share, whereas the estimation was -0.59 USD resulting in a +44.07% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Xilio Therapeutics revenue for the last year?▼
Xilio Therapeutics revenue for the last year amounts to 43.77M USD.
What is Xilio Therapeutics net income for the last year?▼
XLO net income for the last year is -35.04M USD.
How many employees does Xilio Therapeutics have?▼
As of August 22, 2026, the company has 76 employees.
In which sector is Xilio Therapeutics located?▼
Xilio Therapeutics operates in the Health & Wellness sector.
When did Xilio Therapeutics complete a stock split?▼
The last stock split for Xilio Therapeutics was on March 16, 2026 with a ratio of 1:14.
Where is Xilio Therapeutics headquartered?▼
Xilio Therapeutics is headquartered in WALTHAM, United States.